As NLRP3 is already known to promote vascular inflammation and atherosclerosis development [59], its inhibition from colchicine might explain one of the possible mechanisms involved in cardiac protection from this compound in patients with CCS. The gene discussed is NLRP3; the disease is atherosclerosis.